FDA Update on Laboratory Developed Tests Oversight

5
FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division of Human Tissues, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration ACOT Meeting, February 28, 2012

description

FDA Update on Laboratory Developed Tests Oversight. Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division of Human Tissues, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, - PowerPoint PPT Presentation

Transcript of FDA Update on Laboratory Developed Tests Oversight

Page 1: FDA Update on Laboratory Developed Tests Oversight

FDA Update on Laboratory Developed Tests Oversight

Laura M. St. Martin, M.D., M.P.H.Acting Branch Chief,Human Tissues and Reproduction Branch,Division of Human Tissues,Office of Cellular, Tissue and Gene Therapies,Center for Biologics Evaluation and Research,Food and Drug Administration

ACOT Meeting, February 28, 2012

Page 2: FDA Update on Laboratory Developed Tests Oversight

Background ACOT meeting (August 23-24, 2011) agenda

item regarding: FDA guidance document on analyte specific

reagents (Sept 2007), and draft guidance on research use only/investigational use only in vitro diagnostics (June 2011)

Concerns over FDA proposed plan to provide greater oversight for laboratory developed tests (LDTs)

Specific concerns re: potential effect on the fields of histocompatibility and immunogenetics

Page 3: FDA Update on Laboratory Developed Tests Oversight

FDA Involvement in Public Discussion FDA convened public meeting in July 2010 to

gather input on our intention to propose a regulatory framework to address LDTs

FDA received over 100 comments to public docket for IUO/RUO draft guidance from stakeholders expressing support and concern

FDA has repeatedly stated in public that any framework will be phased in according to risk, and there will be ample opportunity for stakeholders to provide input

Page 4: FDA Update on Laboratory Developed Tests Oversight

Stakeholder Input Encouraged FDA will consider concerns raised as we

develop policies applicable to analyte specific reagents and laboratory devices indicated for research use only, including concerns related to the needs of small patient populations

FDA encourages commentary from stakeholders to inform its development of policy related to these reagents, tests, and devices

Page 5: FDA Update on Laboratory Developed Tests Oversight

FDA Commitment FDA recognizes

value of high quality histocompatibility and immunogenetic tests in achieving OPTN goals

value and need for availability of tests for high-resolution HLA typing in unrelated donor hematopoietic stem cell transplantation

FDA will provide additional opportunity for input and discussion before taking new steps toward regulation of LDTs used in organ and stem cell transplantation


Fda communications-oversight-in-a-digital-era

Fda communications-oversight-in-a-digital-era

FDA Oversight of the Tissue Bank Industry

FDA Oversight of the Tissue Bank Industry

SPOT/Dx Diagnostic Quality Assurance Pilot · – Advent of NIH Precision Medicine Initiative (PMI) – FDA January 2017 LDT oversight discussion paper – Existing standardization

SPOT/Dx Diagnostic Quality Assurance Pilot · – Advent of NIH Precision Medicine Initiative (PMI) – FDA January 2017 LDT oversight discussion paper – Existing standardization

Guidance for Industry and FDA Staff · Guidance for Industry and FDA Staff Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery

Guidance for Industry and FDA Staff · Guidance for Industry and FDA Staff Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery

FDA Oversight of PET Drug Products: Questions and Answers€¦ · Guidance FDA Oversight of PET Drug Products Questions and Answers U.S. Department of Health and Human Services Food

FDA Oversight of PET Drug Products: Questions and Answers€¦ · Guidance FDA Oversight of PET Drug Products Questions and Answers U.S. Department of Health and Human Services Food

Identifying Problematic Claims in Your (and Your …...CDRH - Oversight of Device Ad/Promo FDA Oversight of Advertising and Promotion Effective November 2013, Office of Compliance

Identifying Problematic Claims in Your (and Your …...CDRH - Oversight of Device Ad/Promo FDA Oversight of Advertising and Promotion Effective November 2013, Office of Compliance

Guidance for Industry and FDA Staff Pharmacogenetic … Nonbinding Recommendations 1 Guidance for Industry and FDA Staff Pharmacogenetic Tests and Genetic Tests for Heritable Markers

Guidance for Industry and FDA Staff Pharmacogenetic … Nonbinding Recommendations 1 Guidance for Industry and FDA Staff Pharmacogenetic Tests and Genetic Tests for Heritable Markers

Another Look at Free Markets – Regulating and Evaluating Genetic Tests Lawrence Silverman May 30, 2009 Oversight of Genetic tests – Roles of FDA, CDC,

Another Look at Free Markets – Regulating and Evaluating Genetic Tests Lawrence Silverman May 30, 2009 Oversight of Genetic tests – Roles of FDA, CDC,

Project On Government Oversight - pogoarchives.orgpogoarchives.org/m/fda/...dangerous_decision_making_at_the_fda...Dangerous Decision-Making at the FDA October 15, 2015 . 1 ... hemorrhage,

Project On Government Oversight - pogoarchives.orgpogoarchives.org/m/fda/...dangerous_decision_making_at_the_fda...Dangerous Decision-Making at the FDA October 15, 2015 . 1 ... hemorrhage,

GAO-09-250 Dietary Supplements: FDA Should Take Further … · DIETARY SUPPLEMENTS FDA Should Take Further Actions to Improve Oversight and Consumer Understanding Highlights of GAO-09-250,

GAO-09-250 Dietary Supplements: FDA Should Take Further … · DIETARY SUPPLEMENTS FDA Should Take Further Actions to Improve Oversight and Consumer Understanding Highlights of GAO-09-250,

Emerging Issues in FDA’s Oversight of Clinical Research David A. Lepay, M.D., Ph.D. Senior Advisor for Clinical Science FDA Science Board Meeting November.

Emerging Issues in FDA’s Oversight of Clinical Research David A. Lepay, M.D., Ph.D. Senior Advisor for Clinical Science FDA Science Board Meeting November.

Use of Standards in FDA Regulatory Oversight of Next ... · PDF fileContains Nonbinding Recommendations Draft – Not For Implementation 1 Use of Standards in FDA Regulatory 2 Oversight

Use of Standards in FDA Regulatory Oversight of Next ... · PDF fileContains Nonbinding Recommendations Draft – Not For Implementation 1 Use of Standards in FDA Regulatory 2 Oversight

An Investigation into Pharmaceutical manufacturing Performance and its relationship to FDA oversight and enforcement actions An Investigation into Pharmaceutical.

An Investigation into Pharmaceutical manufacturing Performance and its relationship to FDA oversight and enforcement actions An Investigation into Pharmaceutical.

FDA Oversight of Cell Therapy Clinical Trials Celia Witten, Ph.D., M.D. Office Director, Office of Cellular, Tissue, and Gene Therapies CBER/FDA ISSCR/CIRM/ISCT.

FDA Oversight of Cell Therapy Clinical Trials Celia Witten, Ph.D., M.D. Office Director, Office of Cellular, Tissue, and Gene Therapies CBER/FDA ISSCR/CIRM/ISCT.

FDA Oversight of Synthetic Biology - Home | The National ...sites.nationalacademies.org/cs/groups/pgasite/documents/webpage/... · FDA Oversight of Synthetic Biology Frank F. Weichold,

FDA Oversight of Synthetic Biology - Home | The National ...sites.nationalacademies.org/cs/groups/pgasite/documents/webpage/... · FDA Oversight of Synthetic Biology Frank F. Weichold,

GAO-11-468 Medical Devices: FDA Should Enhance Its Oversight

GAO-11-468 Medical Devices: FDA Should Enhance Its Oversight

RE: Docket No. FDA 2016 D 1270; Draft Guidance for ... Specific Comments FDA Draft Guidance— Use of Standards in FDA’s Regulatory Oversight of Next Generation Sequencing (NGS)-Based

RE: Docket No. FDA 2016 D 1270; Draft Guidance for ... Specific Comments FDA Draft Guidance— Use of Standards in FDA’s Regulatory Oversight of Next Generation Sequencing (NGS)-Based

FDA Regulation of Drugs of Abuse Tests - samhsa.gov...Drugs of Abuse (DOA) Tests • Tests used to screen for the potential presence of abused drugs in a specimen obtained from a subject

FDA Regulation of Drugs of Abuse Tests - samhsa.gov...Drugs of Abuse (DOA) Tests • Tests used to screen for the potential presence of abused drugs in a specimen obtained from a subject

This list of vendors providing testing services (Vendor ......Covered COVID-19 tests include all FDA-authorized COVID-19 diagnostic tests, COVID19 diagnostic - tests that developers

This list of vendors providing testing services (Vendor ......Covered COVID-19 tests include all FDA-authorized COVID-19 diagnostic tests, COVID19 diagnostic - tests that developers

The Public Health Evidence for FDA Oversighht of …The Public Health Evidence f or FDA Oversight of Laboratory Developed Tests: 20 Case Studies Office of Public Health Strategy and

The Public Health Evidence for FDA Oversighht of …The Public Health Evidence f or FDA Oversight of Laboratory Developed Tests: 20 Case Studies Office of Public Health Strategy and